Review



3d pharmacophore model catalyst/ hypogen program  (Hypogen Inc)

 
  • Logo
  • About
  • News
  • Press Release
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 90

    Structured Review

    Hypogen Inc 3d pharmacophore model catalyst/ hypogen program
    3d Pharmacophore Model Catalyst/ Hypogen Program, supplied by Hypogen Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/discovery+studios+catalyst+hypogen+algorithm/catalyst+hypogen+pharmacophores/pm24735019-44-5-6
    Average 90 stars, based on 1 article reviews
    3d pharmacophore model catalyst/ hypogen program - by Bioz Stars, 2026-11
    90/100 stars

    Images

    Related Articles

    other:

    Article Title: ACE inhibitors from Suaeda salsa : 3D-QSAR modeling, metabolomics, molecular docking and molecular dynamics simulations.
    Article Snippet: Inhibition of ACE is considered as one of the main strategies to reduce hypertension.. ACE inhibitors derived from Suaeda salsa (S. salsa) present a novel antihypertensive agent source.. This study employed 3D-QSAR pharmacophore, metabolomics, docking-based screening, and molecular dynamics simulations to identify ACE inhibitors from S. salsa.

    Article Title: Discovery of new potent lysine specific histone demythelase-1 inhibitors (LSD-1) using structure based and ligand based molecular modelling and machine learning
    Article Snippet: Another approach to assess the quality of Discovery Studio-HYPOGEN pharmacophores is to cross-validate them based on Fisher’s randomization test (Fisher, 1966) via Cat-Scramble program implemented in HYPOGEN.

    Article Title: The Histone Deacetylase Family: Structural Features and Application of Combined Computational Methods
    Article Snippet: Pharmacophore models, notably HypoGen-based 3D QSAR, based on the crystal structure of HDAC6 (PDB ID: 5EDU), have been instrumental in identifying potent HDAC6 inhibitors and assessing their selectivity.

    Article Title: In the quest for histone deacetylase inhibitors: current trends in the application of multilayered computational methods.
    Article Snippet: Histone deacetylase (HDAC) inhibitors have gained attention over the past three decades because of their potential in the treatment of different diseases including various forms of cancers, neurodegenerative disorders, autoimmune, inflammatory diseases, and other metabolic disorders.. To date, 5 HDAC inhibitor drugs are marketed for the treatment of hematological malignancies and several drug-candidate HDAC inhibitors are at different stages of clinical trials.. However, due to the toxic side effects of these drugs resulting from the lack of target selectivity, active studies are ongoing to design and develop either class-selective or isoform-selective inhibitors.

    Article Title: Discovery of novel chemotype inhibitors targeting Anaplastic Lymphoma Kinase receptor through ligand-based pharmacophore modelling
    Article Snippet: Anaplastic Lymphoma Kinase (ALK) is a receptor tyrosine kinase within the insulin receptor superfamily.. Alterations in ALK, such as rearrangements, mutations, or amplifications, have been detected in various tumours, including lymphoma, neuroblastoma, and nonsmall cell lung cancer.. In this study, we outline a computational workflow designed to uncover new inhibitors of ALK.

    Activity Assay:

    Article Title: Lead generation of UPPS inhibitors targeting MRSA: Using 3D-QSAR pharmacophore modeling, virtual screening, molecular docking, and molecular dynamic simulations.
    Article Snippet: .. The 3D QSAR pharmacophore model generation (HypoGen algorithm) protocol was used to generate a valid predictive pharmacophore model using a set of UPPS inhibitors with known reported activity. ..

    Article Title: QSAR Studies to Predict Activity of HSP90 Inhibitors.
    Article Snippet: ur re nt T op ic s i n M ed ic in al C he m is tr y Vaishali M. Patil, Neeraj Masand, Satya P. Gupta and Brian S. J. Blagg 1Department of Pharmaceutical Chemistry, KIET School of Pharmacy, KIET Group of Institutions, Delhi-NCR, Ghaziabad, Uttar Pradesh, India; 2Department of Pharmacy, Lala Lajpat Rai Memorial Medical College, Meerut, Uttar Pradesh, India; 3Department of Applied Sciences, National Institute of Technical Teachers’ Training and Research, Bhopal, MP, India; 4Warren Family Research Center for Drug Discovery and Development, University of Notre Dame, IN, United States

    In Silico:

    Article Title: QSAR Studies to Predict Activity of HSP90 Inhibitors.
    Article Snippet: ur re nt T op ic s i n M ed ic in al C he m is tr y Vaishali M. Patil, Neeraj Masand, Satya P. Gupta and Brian S. J. Blagg 1Department of Pharmaceutical Chemistry, KIET School of Pharmacy, KIET Group of Institutions, Delhi-NCR, Ghaziabad, Uttar Pradesh, India; 2Department of Pharmacy, Lala Lajpat Rai Memorial Medical College, Meerut, Uttar Pradesh, India; 3Department of Applied Sciences, National Institute of Technical Teachers’ Training and Research, Bhopal, MP, India; 4Warren Family Research Center for Drug Discovery and Development, University of Notre Dame, IN, United States



    Similar Products

    90
    Hypogen Inc discovery studio's catalyst hypogen algorithm
    Discovery Studio's Catalyst Hypogen Algorithm, supplied by Hypogen Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/discovery+studios+catalyst+hypogen+algorithm/discovery+studio+2+5/10__22270_slash_ujpr__v8i5__1008-60-1-4
    Average 90 stars, based on 1 article reviews
    discovery studio's catalyst hypogen algorithm - by Bioz Stars, 2026-11
    90/100 stars
      Buy from Supplier

    Image Search Results